Senior Data Science Lead — Biomarkers & Multimodal AI

Bristol Myers Squibb; Brisbane (CA); On-site; USD 170,000 - 207,000; Full time

Job summary

Bristol Myers Squibb seeks a Senior Manager, Data Scientist to advance drug development through advanced computational methods and biomarker analyses. You will translate multimodal clinical and omics data into testable hypotheses, building predictive models and leading statistical strategy across projects.

You will collaborate with clinicians, data scientists, statisticians and IT, delivering high‑impact insights while guiding biomarker qualification and assay development for scalable clinical

Qualifications

• Ph.D. in a quantitative field or Master’s with relevant experience.
• Hands-on experience analyzing omics or molecular assay data.
• Experience with AI/ML and data science in pharma R&D.

Responsibilities

• Develop and apply computational methods for biomarker and patient stratification.
• Collaborate with statisticians to write SAPs and analysis plans.
• Execute analyses on clinical trials and real‑world data.
• Build predictive models and scalable modeling pipelines.
• Contribute to drug development strategy with statistical insights.
• Validate biomarker assays for clinical trial use.
• Communicate results with cross‑functional teams.

Skills

Statistical modeling

Machine learning

Data analysis

Programming (Python/R/SQL)

Bioinformatics knowledge

Cross-functional collaboration

Communication skills

Education

Ph.D. in Computational Biology/Biostatistics/Statistics/CS

Or Master’s with 3+ years industry exp.

Tools

SQL

Python

R

Cloud platforms

Job description

Bristol Myers Squibb seeks a Senior Manager, Data Scientist to advance drug development through advanced computational methods and biomarker analyses. You will translate multimodal clinical and omics data into testable hypotheses, building predictive models and leading statistical strategy across projects.

You will collaborate with clinicians, data scientists, statisticians and IT, delivering high‑impact insights while guiding biomarker qualification and assay development for scalable clinical